PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

Future Medicine

1 Papers Indexed in Blossom

Data updated October 28, 2025

Research Footprint

Future Medicine has 1 tracked paper indexed in Blossom (2022) from 7 authors, most often covering Ketamine and Esketamine, across Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD) and Depressive Disorders.

Published Papers

Paywallindividual

Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study

This retrospective analysis (n=171) examined the effectiveness of esketamine in participants with treatment-resistant depression (TRD). A significant reduction in depressive symptoms was observed using the PHQ-9 and GAD-7 from baseline to last the last treatment.

Published
November 4, 2022
Journal
Future Medicine
Authors
Brendle, M., Ahuja, S., Della Valle, M., Moore, C., Thielking, P., Malone, D. C., Robison, R.

Quick Facts

Papers Indexed
1
Publisher
Future Science Publishing Group
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.